“The Latest on the Pox Outbreak: Which Pharmaceutical Stocks are Poised to Meet the Market Demand? – Analysis and Breakdown”
On August 14th, the World Health Organization (WHO) declared the pox outbreak a public health emergency of international concern (PHEIC). This designation triggers a coordinated international response under the International Health Regulations (IHR), potentially leading to vaccination efforts.
With over 17,000 cases tracked mainly in central Africa, the latest pox strain named Clade 1 could spread further due to international travel. This raises the question – which pharmaceutical stocks are equipped to address the pox market demand?
1. Bavarian Nordic:
– Offers Jynneos vaccine for smallpox and monkeypox
– Traditional vaccine model
– Expected revenue of up to $445 million in 2024
– Stock up 51% year-to-date
2. Emergent BioSolutions:
– Developed ACAM2000 live vaccine for smallpox
– Stock up 336% year-to-date
– Recently secured a $250 million contract
– Stock priced at $11.38
3. SIGA Technologies Inc:
– Offers tecovirimat oral antiviral drug treatment
– Showed strong safety profile in PALM 007 study
– Secured government contracts worth $113 million
– Stock up 73% year-to-date
In conclusion, these pharmaceutical companies are at the forefront of addressing the pox outbreak and have the potential to generate significant revenue. Investors should keep a close eye on these stocks as they navigate the evolving situation and contribute to global health efforts.